Physician profile
John B Tilmon
NPI 1619903721
$2,982.31
in general payments reported to CMS, 2019-2025
23 companies · $968 in 2025
The $968 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $666 · 2022: $233 · 2023: $453 · 2024: $663 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027 · Education: $56.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.12 |
| Education | $56.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $892.74 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $458.42 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $298.82 | 2024-2025 | Rexulti, Nuedexta |
| Novo Nordisk INC | $239.32 | 2021-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.45 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $141.19 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $122.48 | 2021-2025 | Airsupra |
| Ardelyx, INC. | $113.85 | 2025 | Ibsrela |
| Abbott Laboratories | $99.89 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $87.35 | 2024-2025 | Veozah |
| Pfizer INC. | $57.11 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $50.71 | 2025 | Austedo Xr |
| Avanir Pharmaceuticals, INC. | $48.84 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $45.83 | 2025 | |
| Exact Sciences Corporation | $34.89 | 2023-2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $22.92 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $19.09 | 2025 | Auvelity |
| Smith+Nephew, INC. | $15.38 | 2023 | Collagenase Santyl, Regranex |
| Amgen INC. | $15.34 | 2024 | Prolia, Evenity |
| Sumitomo Pharma America, INC. | $14.98 | 2023 | Gemtesa |
| Esperion Therapeutics, INC. | $14.06 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $12.74 | 2023 | Trelegy Ellipta |
| Genentech USA, INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tilmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.